Table 5 Canakinumab initiation patterns among patients with PFS

Age when first prescribed canakinumab (years), mean (SD)

20.7 (15.9)

9.1 (4.3)

30.7 (15.5)

22.9 (17.8)

20.4 (14.6)

19.8 (19.4)

17.4 (12.3)

 2016

8 (5.4)

2 (2.9)

6 (7.6)

4 (6.8)

1 (2.5)

0 (0.0)

3 (7.1)

 2017

58 (39.5)

27 (39.7)

31 (39.2)

26 (44.1)

15 (37.5)

5 (45.5)

15 (35.7)

 2018

81 (55.1)

39 (57.4)

42 (53.2)

29 (49.2)

24 (60.0)

6 (54.5)

24 (57.1)

Canakinumab initial dose (reported by physician as mg/kg or calculated mg/kg when weight was available), mean (SD)

2.8 (1.8) [N=144]

3.3 (2.2) [N=67]

2.3 (1.1) [N=77]

3.0 (2.2) [N=57]

2.3 (0.7) [N=40]

2.4 (1.3) [N=10]

3.0 (1.8) [N=41]

Initial dose among physicians who reported mg/kg, mean (SD)

2.9 (1.9) [N=67]

2.9 (2.0) [N=47]

2.9 (1.5) [N=20]

3.3 (2.3) [N=27]

2.0 (0.0) [N=12]

2.2 (0.4) [N=6]

3.0 (1.7) [N=24]

Initial dose among physicians who reported mg

N=80

N=21

N=59

N=32

N=28

N=5

N=18

Mean (SD)

134.2 (46.9)

123.3 (38.1)

138.1 (49.4)

138.7 (54.0)

134.8 (39.3)

112.4 (60.2)

133.9 (38.5)

Median (Q1, Q3)

150.0 (150.0, 150.0)

150.0 (100.0, 150.0)

150.0 (150.0, 150.0)

150.0 (150.0, 150.0)

150.0 (150.0, 150.0)

150.0 (100.0, 150.0)

150.0 (150.0, 150.0)

 Every 4 weeks

73 (49.7)

36 (52.9)

37 (46.8)

19 (32.2)

23 (57.5)

6 (54.5)

26 (61.9)

 Every 8 weeks

74 (50.3)

32 (47.1)

42 (53.2)

40 (67.8)

17 (42.5)

5 (45.5)

16 (38.1)

 Yes

67 (45.6)

29 (42.6)

38 (48.1)

26 (44.1)

20 (50.0)

5 (45.5)

18 (42.9)

 No

80 (54.4)

39 (57.4)

41 (51.9)

33 (55.9)

20 (50.0)

6 (54.5)

24 (57.1)